Hematopoietic stem cells have dissimilar proliferative capacities; although some remain in quiescence, some consistently undergo multiple rounds of cell division stimulating hematopoiesis to maintain homeostasis and protect stem cell exhaustion. The stringent equilibrium between quiescence, self-renewal, proliferation, and differentiation is maintained by the operational selectiveness of intrinsic factors and extrinsic cues provided by the specialized microenvironment called the "niche" that provides homeness to hematopoietic stem cells (HSCs). The niche is defined by a heterogeneous identity involving the complex interaction of various other cells, cytokines, adhesion molecules, and extracellular matrix via several surface receptors and soluble factors, which work in paracrine coordination and protect stem cells from depletion while eliciting proliferation. The widespread investigations have shed light on the mechanistic underpinnings in niche, which coordinate the balance between relative hematopoietic quiescence and proliferation. In this paper, we discuss the recent findings concerning how these complex niche interactions facilitate the regulation of hematopoietic stem cells during homeostasis and further extend the discussion to their involvement in expansion and tumorigenesis, the two biological phenomena that are intimately associated with stem cells.
Introduction
Hematopoietic stem cells (HSCs) are well-appreciated adult stem cells through quantitative functional assays and prospective isolation methods. Nevertheless, the rigorous identification and isolation of HSCs is based on the expression of several cell surface markers (1) . Murine HSC activity resides in a population of adult bone marrow (BM) cells that do not express any of the several surface markers found on different more mature blood cells (lineage neg; "L") but express the markers c-Kit (CD117; "K") and stem cell antigen 1 (Sca-1; "S"). Initially, the study revealed that when individually transplanted, only 30%-40% of the CD34 −/low c-Kit . In mice, co-expression of CD34 and CD105 display relatively more specificity for the most immature, long-term repopulating HSCs. Recently, CD105, which is expressed on 30%-80% of CD34 cells, is also a marker for human long-term repopulating HSCs (2, 3) . SLAM family markers remain stable across mobilization and multi-lineage reconstitution, and they are less affected by age and genetic background of mice. In addition, use of SLAM markers reduces the number of markers that need to be used simultaneously, thereby allowing HSC identification in microscopic analyses in situ (4) (5) (6) . Various markers in combination can be used to purify functional HSCs to approximately 50% (7) . Recently, Quesenberry et al. (8) established that long-term repopulating HSCs continuously alter their phenotype, challenging the purification process. Furthermore, tissue microvesicles cause short-term or long-term epigenetic modulation of the phenotype of stem cell population (8) . Therefore, defining stem cells pose a major challenge for basic HSC research. Another systematic approach to identify and purify stem cell populations relies on HSC-specific functional properties such as low metabolic activity, low staining with the rhodamine 123 dye, and high activity in pumping out the fluorescent dye Hoechst 33342, leading to a "side population" of cells with low fluorescent intensity (2) . These "side population" HSCs show higher expression of stem cell-associated genes such as c-Kit, CD34, Tal-1, and Slamf1 (9) . The gold standard for assessing HSC function in vivo is functional assays that enable precise retrospective quantification of HSC numbers in a given cell population (1, 10). Serial transplantation assay involves transfer of purified HSCs or HSC-enriched donor BM cells into irradiated recipient animals and the subsequent transfer of engrafted donor-derived BM cells from primary to secondary recipients and beyond. The number of successful serial transplantations of the donor's BM is a measure of the self-renewal capacity of HSCs (1) . Serial transplantation of clonal HSC progeny demonstrated that HSC numbers could not only be maintained but could also be expanded in vivo. The ability to reconstitute HSCs into the BM of an irradiated host recipient upon transplantation distinguishes LTHSCs (c-Kit , which have a reconstitution ability that is limited to several weeks (11) . Competitive repopulation unit assay examines the engraftment ability of the experimental longterm HSC population in the presence of a congenic control BM population (1) . One CRU can regenerate up to 15 CRU on average after transplantation into lethally irradiated mice (12) . Recently, Purton et al. (13) reviewed that the best single assay for quantifying HSC content is the limiting dilution assay.
Despite the extensive characterization of HSCs, mechanisms governing HSC proliferation and differentiation are poorly understood. Analyses of in vivo and in vitro colony-forming cells led to the concept of a stochastic model for HSC behavior (14) . The hematopoietic inductive microenvironment and stem cell competition models support that extrinsic factors play an instructive role rather than a permissive role (15) . The fate choice of HSCs, at least in part, is ordained by niche signaling (Figure 1 ), regardless of HSC stochastic (probabilities) or deterministic (precise) instructions for self-renewal (16) . It is assumed that local environments called stem cell niches control the homeostasis of hematopoietic stem and progenitor cells (HSPCs). Study of the HSC niche took a great stride following advances in imaging capabilities and mouse genetics.
Cellular components of niche
Stem cell niche was introduced by Ray Schofield in 1978 (17) . Stem cell niche is a functionally specialized microenvironment, which nurses adult hematopoietic cells and non-hematopoietic stromal cells, including osteoblasts, osteoclasts, mesenchymal stromal cells (MSCs), adipocytes, endothelial cells, fibroblasts, and macrophages. It also includes physical factors, such as oxygen tension, to regulate HSC quiescence, cell cycle, self-renewal, and differentiation (6) . Functional heterogeneity within the HSC population delineates the topological organization of HSCs (18) . Recently, the following three main types of niches have been recognized: the endosteal (osteoblastic), reticular, and vascular (endothelial) (Figure 2 ). Endosteal niche mainly consists of the "spindle-shaped N-cadherin + CD45
− osteoblastic (SNO) cells. " Self-renewal capacity is better in endosteal HSCs than other niche HSCs (19) . The endothelial sinusoids are encompassed by MSCs, which are identified as pericytes. The diverse and distinct niches composed of different stromal cells work cooperatively to balance the crucial steps of hematopoietic cascade. Stromal subpopulation can be further classified by their expression of distinctive nestin and leptin receptors. Nestin-positive cells express high levels of leptin receptor transcripts, which implies an overlap between osteoblastic and perivascular niches (20) . The reticular niche is diffusely developed in the BM and largely secretes SDF-1 (CXCL12); it has been named as CXCL12 abundant reticular (CAR) cells. CAR cells are important in the homing and localizing HSCs within the BM endosteum in response to calcium-sensing receptors (21) . Imaging analyses have shown that HSCs are preferentially located near blood sinusoids rather than near osteoblasts. Fast-cycling committed progenitors and differentiated cells are preferentially distributed in the central and perisinusoidal regions, respectively (22) . Increasing evidence indicates that perivascular niches are subjected to different signals when situated near osteoblasts compared with signals associ- ated with perivascular niches when they are situated away from osteoblasts. Despite these insights, the significant barrier to the study of sinusoidal epithelial cells has been the lack of specific cell surface markers for their isolation. The recent finding that BM sinusoidal epithelial cells can scavenge soluble waste molecules, such as advanced glycation end-products, can be utilized to label BM sinusoidal epithelial cells for cell sorting and isolation (23) .
Hypoxia and oxidative stress
HSCs reside predominantly at the lower terminus of the oxygen gradient within the BM, which serve to protect them from oxygen radicals (24) . The low level of reactive oxygen species (ROS), particularly hydrogen peroxide (H 2 O 2 ) in quiescent HSCs in the endosteal niche preserves the self-renewal function of HSCs and protects against the debilitation of stem cells, whereas a higher level of H 2 O 2 in the vascular niche expedite the proliferation of progenitors. Mechanistically, ROS appear to decrease adhesion molecule expression and stimulate the p38/MAPK pathway causing dormant HSCs to cycle repeatedly and become exhausted. FOXO subfamily of forkhead transcription factors is involved in safeguarding HSCs from oxidative stress by up-regulating detoxifying genes (16, 25) . In response to ischemic injury, ROS get increased in the BM niche, from NADPH oxidase in mitochondria, to express hypoxia-inducible factor (HIF)-1α. Up-regulation of HIF1α in HSCs leads to a shift away from mitochondrial oxidative phosphorylation toward glycolysis, which facilitates HSC survival in hypoxic microenvironment (26) . However, the deletion of HIF1α has been shown to induce HSC proliferation and consequent exhaustion of repopulating capacity. Enigmatically, the over-stabilization of HIF1α also leads to HSC loss. Thus, there may exist a narrow window in which the oxygen tension is optimal for HSC maintenance (27) .
Molecular regulators that mediate signaling between stem cells and their niches
Regulatory interactions between HSCs and osteoblasts are mediated by growth factors, chemokines, cell-cell interactions, cellmatrix interactions, and signaling pathways (Wnt, Notch, and Shh pathways) (16) . These niche regulators act in combination to regulate HSC quiescence, self-renewal, differentiation, and maintenance.
Secreted ligands and their receptors
HSCs respond to a multitude of external factors to maintain hematopoiesis and to increase HSC yield during hematopoietic stress. Indeed, various ligand-receptor pairs (angiopoietin-1 and TIE2, SCF and c-KIT, SDF-1 and CXCR4, thrombopoietin (TPO) and myeloproliferative leukemia virus oncogene (MPL) play preeminent role in HSC homing, migration, quiescence, self-renewal, and proliferation (28, 29) (Figure 3 ). SDF-1 and CXCR4 interactions are not only involved in HSC homing but also in the survival and maintenance of quiescent HSCs in BM niche. The molecular signaling cascade including cAMP, phosphatidylinositol-4,5-biphosphate 3 kinase (PI3K), a number of GTPases, and protein kinase C isoform ζ (PKC-ζ) contribute to enhance the expression of CXCR4 on HSCs (30) .
Prostaglandin (PGE) derivate, 16,16-dimethyl-PGE2 (dmPGE2), secreted by osteoblasts increases CXCR4 expression on HSCs, thereby augmenting HSC migration to SDF-1 and homing to the BM (31). PGE2 also reinforces HSC survival by increasing the expression of anti-apoptotic protein, "surviving" on HSCs. Stem cell factor (SCF) is an important chemokine produced by SNO and CAR cells in niche that interacts with c-KIT (CD117). Low c-KIT expression enhances self-renewal and long-term reconstitution of HSCs, whereas high c-KIT expression gives rise to lymphomyeloid grafts and exhibits preference for intrinsic megakaryocytic lineage (32) . Though previous studies established that SCF is produced in BM stromal cells, Ding et al. (33) recently revealed that SCF is principally expressed by perivascular cells in the BM. Signaling of c-KIT, CXCR4, and other receptors (PGE2 receptors) depend on guanine nucleotide binding protein complexes (Gi and Gs) and downstream small GTPases (Rac1, Rac2, and cdc42). Conditional deletion or pharmacological inhibition of genes encoding these proteins undermines HSPC homing (34) . Hematopoietic mobilization involves the disruption of mechanisms that retain HSPCs within the BM. Exogenous or endogenous G-CSF addition disrupts SDF-1/CXCR4 signaling axis to release HSPCs from niche. The mobilizing agent CXCR4 inhibitor plerixafor (AMD3100) interacts synergistically with G-CSF to distort SDF-1/CXCR4 interaction (30) . However, murine studies showed that the elimination of c-KIT resulted in the poor mobilization of HSCs with plerixafor. Thus, the c-KIT kinase activity is considered indispensable for the mobilization of HSCs (34) . In another experiment, the functional blockade of c-KIT with a neutralizing antibody resulted in HSC migration from the BM to the blood (35, 36) . Angiopoietin-3 (expressed by endothelial cells) primarily controls HSC quiescence (37) . Angiopoietin-1 (secreted by osteoblasts) interacts with TIE2 (on LT-HSCs) to upregulate N-cadherin. In turn, N-cadherin positively regulates cyclin-dependent kinase inhibitor p21 to promote adhesion and maintain HSC quiescence (38) . TPO/MPL pathway promotes HSC quiescence by triggering downstream This model depicts the direct physical interaction between the HSC and osteoblasts. Hematopoietic stem and progenitor cells express a number of adhesion receptors on their surfaces that allow them to interact with a large number of adhesive ligands. Ncadherin is expressed on both the SNO cell and HSC and form an adhesive junction. The interaction of the integrin (VLA-4,5) with VCAM and fibronectin is also involved in the HSC-niche adhesion. Once appropriately localized within the quiescent niche, processes such as self-renewal, maintenance of quiescence, and exit from the niche followed by proliferation and differentiation are highly controlled by growth factors and cytokines locally secreted by osteoblasts and stromal cells. The SNO cell provides inhibitory signals, such as Ang-1 and TPO, to restrict HSCs from activation and protect HSCs from differentiation and apoptosis. Wnts and PTH control HSC cycling and modulate the activity of osteoblasts. Wnt signal induced β-catenin activation, and nuclear transfer is also critical for HSC activation and proliferation.
cyclin-dependent kinase inhibitors (CDKIs) such as p57kip2 (39) . Megakaryocytes preserve HSC quiescence through TGFβ-SMAD signaling. However, under hematopoietic stress, fibroblast growth factor (FGF)-1 signaling from megakaryocytes transiently prevails over TGF-β inhibitory signaling to stimulate HSC expansion (40) . Therefore, megakaryocytes not only maintain HSC quiescence during homeostasis but also support hematopoietic recovery following chemotherapeutic stress. Furthermore, megakaryocytes secrete chemokine CXCL4 (or platelet factor 4 or PF4), which curtails the increasing number of HSCs by driving HSCs to quiescence (41) . A novel neurotrophic factor receptor explored recently, named as RET, drive HSC survival, expansion, and in vivo BM reconstitution, thereby opening avenues for further investigations of RET agonists for successful HSC transplantation (42) . RET signals provide vital surviving cues such as Bcl2 and Bcl2l1 downstream of p38 mitogen-activated protein kinase and activated cyclic AMP response element-binding protein. Apparently, primitive hematopoietic cells are intrinsically programmed to undergo differentiation as directed by retinoid acid unless BM stromal cell CYP26 inactivates the retinoid acid. Modulation of retinoid acid signaling also promotes robust HSC expansion (43) .
The adaptor protein Lnk downregulates the self-renewal of primitive stem cells by attenuating TPO-induced signaling pathways that lead to the activation of downstream signaling proteins such as mpl and JAKs (44) (45) (46) . The CD164 receptor sialomucin expressed on the surface of primitive hematopoietic cells and associated stromal/endothelial cells mediate the adhesion of hematopoietic precursor cells to stroma and serve as potent downregulating factor for hematopoietic proliferation (47) . Osteopontin (OPN) is another negative regulator of niche function. OPN-null microenvironment results in augmentation in HSC number, increased expression of stromal Jagged1 and angiopoietin-1, and reduction in apoptosis (48) . Recently, Larsson et al. (49) suggested that Nf2/merlin restrains HSC number by modifying niche architecture. Nf2-lacking HSCs displayed the expansion of HSCs with concurrent increase in VEGF. Studies have reported that aryl hydrocarbon receptor negatively modulates hematopoiesis to restrict excessive proliferation (50) .
BM resident regulatory T cells secrete the cytokines IL-3 and GM-CSF for HSC maintenance in the proximity of sinusoids in the perivascular HSC niche during normal hematopoiesis. However, the cytokine milieu of the microenvironment is tailored, and the migration of hematopoietic cells can be changed in response to an infection or BM stress called "demand-adapted hematopoiesis" (51, 52). Rashidi et al. (53) reported that steady-state HSCs reside within confined niches, whereas infection-exposed HSCs become migratory and interact with wider microenvironment regions. These HSCs also show competence for long-term repopulation and expression of CD44 and CXCR4 (53) . Physiological levels of IFNs control HSC turnover and function. Acute interferon-alpha (IFN-α) treatment promotes STAT1-mediated proliferation of dormant HSCs in vivo, whereas chronic IFN-α activation impairs HSC function (54) .
Localization of HSCs after transplantation
BM transplantation offers a major illustration of the regenerative efficiency of the HSC niche (55) . Initially, HSCs, primarily quiescent HSCs, home on the endosteal surface. Gradually, proliferating and differentiating progenitor cells migrate centripetally in the endosteal niche (56) . Quiescent and mitotically active transplanted HSCs display varying abilities for engraftment and BM repopulating potential (57) . Outcome of the transplanted HSCs is decided through complex bidirectional interactions with various stromal cell components in the niche (58) . It was earlier thought that transplanted HSCs localize to the osteoblasts through a specific interaction via the type-1 transmembrane protein N-cadherin on both the osteoblast cell and HSC surface (59) . However, there are conflicting results in the literature regarding the critical nature of the N-cadherin interaction with HSCs (60). Recently, SMAD-dependent BMP signaling was reported as a novel inhibitor of CXCL12 production in the BM niche. The BMP antagonist noggin elevated CXCL12 levels in BM plasma leading to enhanced homing and engraftment of transplanted HSPCs. SMAD-binding element was identified in the CXCL12 promoter to which SMAD4 binds. Infusion of BMP7, but not BMP4, depreciates HSPC homing. BMP7 infusion results in the mobilization of only ST-HSCs because BMP7 affects CXCL12 expression only in osteoblasts, but not in other niche components (61) . Conditional deletion of essential pathways involved in HSPC retention (VCAM-1/α4 integrin, CXCL12/CXCR4 interactions) motivates substantial HSPC mobilization into the blood. In response to G-CSF or chemotherapy, BM myeloid cell expands with high oxygen consumption, resulting in hypoxia. This leads to the activation of neutrophils and macrophages with the release of neutrophil proteases such as neutrophil elastase, cathepsin G, matrix metalloproteinase-9, and membrane type-1 matrix metalloproteinase with collateral down-regulation of their naturally occurring inhibitors of metalloproteinases. These proteases are intriguing candidates to mediate mobilization as they cleave and inactivate a range of proteins involved in HSPC retention within the BM such as VCAM-1, SDF-1/ CXCR4 and c-KIT/SCF. HSC egression is mediated by heterotrimeric guanylate-binding protein Gi, which inhibits adenyl cyclase and the formation of cAMP, and Rho family GTPases (Rac1 and 2, and cdc42) (34, 62) . Presently, a number of mechanisms responsible for mobilization have been proposed. Nevertheless, how these mechanisms are hindered following the clinical administration of G-CSF or cytotoxic therapy for HSC mobilization is still not thoroughly explicated. Intriguingly, many of the proposed mechanisms merge to the CXCR4/SDF-1α pathway. Treatment with non-steroidal antiinflammatory drugs (NSAIDs) in mice inhibits endogenous PGE2, resulting in moderate HSC emigration, superior hematopoietic repopulating ability, and long-term engraftment unrelated with SDF-1-CXCR4 signaling. PGE2 receptor knockout mice showed that HSPC egression emanated from reduced E-prostanoid 4 (EP4) receptor signaling (63) . Further investigations on pathways and mechanisms that actively mediate the egression of HSPCs from BM into circulation could be useful to mobilize HSPCs.
Wingless and int signaling
Lipid-modified Wingless and int (Wnt) proteins are short-range cellular signals emanating from the niche to regulate HSC self-renewal and maintenance (64) . In canonical Wnt signaling, Wnt proteins bind to the receptors of the frizzled-and lipoprotein-related protein receptors on the cell surface. On ligand binding, frizzled protein forms a complex with disheveled (Dsh) protein. Subsequently, degradation complex (axin, APC, GSK3β) is dissipated and β-catenin accrues and translocates to the nucleus where it associates with the transcription factor T-cell factor/lymphoid enhancer factor (TCF) to trigger the transcription of Wnt target genes ( Figure 2 ). Exposure to purified Wnt3a resulted in increased self-renewal of both murine and human HSCs, as determined by murine in vivo reconstituting assays, immunophenotypic analysis, and colony assays (65, 66) . However, the intracellular mechanisms through which Wnts influence the fate of hematopoietic stem cells remains controversial mostly because of the conflicting results obtained by various gain-and loss-of-function approaches. It has now become clear that Wnt is regulated in a dosage-dependent fashion at indispensable checkpoints in various hematopoietic lineages. HSCs both require and endure only relatively low levels of Wnt signaling. Paradoxically, complete absence of Wnt signaling in HSCs severely impairs the repopulating capacity of HSCs (67).
Non-canonical mechanisms employ the planar cell polarity pathway (PCP) and the Wnt-Ca 2+ pathway. Regulation of PCP pathway requires β-catenin and LRP as co-receptors. Wnt signals through tyrosine kinase receptors, particularly ROR and "related-to-receptor tyrosine kinase" (RYK) receptors in non-canonical signaling modes of Wnt signaling. This pathway stimulates downstream Jun NH2-terminal kinase (JNK), CaMKII, and PKC pathways (68) . Inhibition of RYK blocks the ability of Wnt5a to prompt HSC quiescence and augment short-and long-term hematopoietic repopulation. Ryk regulate the ability of Wnt5a to block ROS production (69). Canonical and non-canonical pathways cooperate with each other; in some cases, non-canonical signaling turns off the canonical pathway (70) . Wnt5a promotes murine HSC quiescence and in vivo repopulation by suppressing the Wnt3a-mediated canonical Wnt pathway (71) . There is experimental evidence for the explicit role of Wnt signaling through its impact on the HSC niche (72 -NFAT-IFNγ pathway through the CDC42-CK1α complex as well as counteracts canonical Wnt signaling in HSCs (73) . An important role for Wnt signaling is the in vitro expansion of HSCs contrary to its function in vivo. In vivo injection of Wnt5a conditioned medium in immunodeficient mice resulted in increased reconstitution and more primitive hematopoietic cells in vivo, whereas in vitro proliferation remains unaffected (74) .
It has been reported from studies in zebra fish and mouse models that PGE2 interacts synergistically with Wnt signaling to increase the number of HSCs, implying a cross-talk signaling between these two pathways (75). However, PGE2 in mice preferentially causes the proliferation of hematopoietic progenitors, but not of HSCs (76) . Secreted Wnt antagonists (frizzled-related protein-1 and -2, Wnt inhibitory factor-1, Dickkopf-1, and sclerostin) either bind to Wnt ligands directly or indirectly by inhibiting Wnt receptors to terminate Wnt signaling as observed in both osteolineage and hematopoietic cell types (77) . Osteoblast-specific overexpression of pan-inhibitor of canonical Wnt signaling, namely Dickkopf homolog 1 (DKK1) detriments HSC self-renewal ability and concordantly decreases p21Cip1 expression (78) (Figure 3) . Further, the expression of Wnt inhibitory factor 1 in osteoblasts demonstrates similar phenotype as observed following over-expression of DKK1. This reveals interaction between Wnt and other signaling pathways (79). Schaniel et al. (79) showed that changes in Wnt signaling in HSC niche is in accordance with other pathways, including the hedgehog pathway. Similarly, the knockout of another negative modulator, secreted frizzled-related protein-1, leads to an initial increase in the number of LT-HSCs; however, they are prematurely exhausted at the end (80). Staal et al. (67) revealed that Wnt secrete a component of extracellular matrix, decorin that mediates the cross-talk between MSCs and HSCs. Study showed that decorin-deficient mice demonstrated extramedullar hematopoiesis and increased number of LT-HSCs (CD150 + LSK) (67) . Wnts are involved in cross-talk with multiple additional signaling cascades, including the Notch, FGF, Shh, epidermal growth factor (EGF), and Hippo pathways (81) . It has been suggested that Wnt and Notch signaling interact mutually. Gsk-3β is a potential candidate to negotiate this cross-talk because it regulates the stability/degradation of both β-catenin and NICD. Inhibition of Gsk-3β influences HSC function by a mechanism involving both Wnt and Notch target genes (82) . However, the molecular mechanisms are not yet well-known.
Notch signaling
Notch is a highly conserved signaling pathway that maintains tissue homeostasis during adult life and modulates cell fate during embryonic development. Essentially, Notch-mediated communication depends on the distinct expression of specific ligands (Jagged 1, Jagged 2, or delta) and redundant Notch receptor homologs (Notch-1, Notch-2, Notch-3, or Notch-4) in adjacent cells. When ligands of the Delta 1-3 or Jagged 1-2 families connect to the Notch receptor, proteolytic events involving γ-secretase lead to release and translocation of the intracellular domain of the receptor (NICD) to the nucleus. NICD will form a complex with the transcription factor CSL and cofactors of the mastermindlike (MAML) family and turns on the transcription of target genes ( Figure 3) . CSL-MAMLs-NICD complex (performing as a transcriptional activator) then stimulates the expression of bHLH protein family of transcriptional repressors such as the Hairy enhancer of split (Hes) and Hairy-related (Hey or Hrt) Notch target genes (83) . Additionally, Notch is represented by communication with its Delta-Serrate (DSL) ligands. Ligands from opposing cells (transligands) activate Notch, whereas ligands expressed in the same cell (cis-ligands) inhibit signaling (84) . The most significant function of Notch is its activation of Hes family of genes. Essentially, ordained activation of the Notch signaling pathway or the downstream target Hes-1 increase the long-term self-renewal ability in the in vivo repopulating HSCs (47, 85) . Hes genes are subjected for Notch functions that require the inhibition of one specific cell fate to concede the determination of an alternative fate (lateral inhibition). Hes1 is only necessary for the first stages of T-cell determination, whereas other significant Notch targets, such as pTα and IL7R, are involved in T-cell differentiation (86) . Expression of Notch1 and Notch2 in HSCs is significant with regard to their response to endothelial-derived maintenance factors (87) . Previous studies have demonstrated that the members of the Notch ligand families Delta and Jagged can amplify hematopoietic progenitors in vitro, as measured by reconstitution assays (88) (89) (90) (91) . In one study, conditional deletion of Jagged-1 in endothelial cells resulted in a decrease in phenotypic and functional LT-HSCs at steady state (92) . Over-expression of constitutively active Notch-1 resulted in the immortalization of a cytokine-dependent murine hematopoietic cell line in vivo (93) .
Parathyroid hormone, a central regulator of the osteoblastic HSC niche in the BM, raises Jagged1 levels of Notch function in HSC expansion in vitro (67) . However, the investigation of transgenic mice carrying a dominant negative form of the coactivator mastermind (which specifically blocks all canonical Notch signaling) indicate that Notch plays a redundant role in the maintenance of HSCs in the adult BM (94, 95) .
Notch signaling is multifactorially achieved, in spite of the plausible simplicity of this pathway with no intermediate effectors. Various enzymes can modify the Notch protein post-translationally, thereby modifying its functional properties. Pofut-1 is an O-fucosyl-transferase that catalyzes the O-fucosylation of the extracellular domain of Notch receptors. Furthermore, elongation with addition of O-fucose moieties by the fringe family of glycosyltransferase boosts the extent of Notch to be triggered by ligands of the Delta-like family (Dll1, Dll3, and Dll4) but reduces Notch activation by the Serrate/Jagged family of ligands (Jag1-2). HSCs expressing fucose-deficient Notch receptors displayed decreased self-renewal capability, suggesting that fucosylation-modified Notch receptor represents an innovative extrinsic regulator for HSC engraftment and maintenance of niche (96) .
Intriguingly, Notch and Wnt pathways are synergistically implicated to activate the self-renewal of HSCs through diverse mechanisms. While Wnt signaling promotes the proliferation and viability of HSCs, Notch signaling maintains an undifferentiated state of HSCs (97) . Ontogeny of HSCs provided new understanding about the prominent aspect of Notch in early hematopoietic development (98) . Wnt16 determines the somitic expression of the Notch ligands deltaC (dlc) and deltaD (dld), suggesting that the two pathways govern the fate of HSC. Recently, FGF signaling via FGF receptor 4 (Fgfr4) has been reported to mediate a signal transduction pathway between Wnt16 and Dlc, but not Dld, to delineate HSCs (99) . Further, Notch3 function lies downstream of Wnt16 and is required for HSC specification (100). The interaction of junctional adhesion molecules Jam1a-Jam2a mediates Notch signal transduction to expedite the transduction of appropriate Notch signals from the somite stage to HSC precursor stage (101) .
Sonic hedgehog pathway
The three hedgehog ligands Sonic (Shh), Indian (Ihh), and Desert (Dhh) bind to membrane patched (Ptc) receptors interchangeably to activate the expression of genes encoding Glioblastoma (GLI)-family of transcription factors (Gli-1, Gli-2, Gli-3) (102). Continued hedgehog activation inhibits the expression of specific cell cycle regulators, resulting in the depletion of HSCs. In the absence of ligand, Ptc impedes the activity of another transmembrane protein Smoothened (Smo), thereby antagonizing the pathway (103, 104) . Shh ligand along with other growth factors prompts cycling and multiplication of primitive BM hematopoietic cells under homeostatic conditions in vitro (105) . Shh signaling in the HSC niche appears to follow a similar criterion compared with Notch signaling (106, 107) . Shh mediates the proliferation of primitive human hematopoietic progenitors in vitro, possibly through the activation of bone morphogenetic protein (BMP) signaling pathway (106) . However, some studies have reported the dispensable role of shh signaling in adult hematopoiesis (106) (107) (108) .
Targeting the stem cell niche for hematopoietic expansion
The clinical expansion of HSCs is imperative for their extensive utilization in regenerative medicine and gene therapy (109) . Ex vivo stem cell expansion renders an enticing approach as their culture conditions can be precisely defined and efficiently employed in vitro (110) . Effective stem cell amplification involves symmetric self-renewal divisions of HSCs where both daughter cells maintain HSC properties. However, HSCs frequently undergo asymmetric divisions in vitro, defined by the production of one HSC and a more differentiated progenitor (111) . Therefore, the expansion of LT-HSCs is complex in ex vivo systems. Though it is challenging to reproduce niche cellular architecture and functionality, manipulation of hematopoietic niche regulators to achieve HSPC expansion would have major implications to influence transplant outcomes. Initial approaches relied on cytokine mediated HSC expansion. Among various cytokine combinations tried so far, HSCs cultured in the presence of TPO, SCF, IGF-2, and angiopoietin 2 or 3, resulted in substantial increase in the number of repopulating HSCs (112) . Such cytokines that induce abundant proliferation are incapable of hindering differentiation of HSCs in long-term cultures (113) . Cytokines have predominantly permissive role in determining the fate of stem cells. Rather, cytokines are considered as an adjunct in the management of graft dysfunction as they play a major role in the regulation of self-renewal and proliferation (114) . Activation of canonical Wnt β-catenin signaling combined with suppression of the mTOR pathway enabled ex vivo maintenance of human and murine HSCs under cytokine-free conditions (115) . Double mutant mice with activated β-catenin in combination with deleted phosphatase and tensin homologue (Pten) showed a robust expansion of LT-HSCs without differentiation (116) . Administration of glycogen synthase kinase-3 (GSK-3) inhibitor to mice transplanted with HSCs supported hematopoietic repopulation capacity without altering their secondary repopulating ability (117) . Notchtargeting agonistic antibodies used for stem cell expansion and antagonistic antibodies for immunomodulation may reduce the risk of GVHD (118) . Potential efficacy of Notch mediated expansion of hematopoietic progenitors is under Phase I clinical trial (109) . Pharmacological use of PTH increases the number of stem cells mobilized into the peripheral blood. This allows more stem cell yield, thereby accumulating stem cells in transplant recipients and shields stem cells from the repetitive exposure to cytotoxic chemotherapy (37, 119) . Systemic over-expression of Shh in mice mediates the expansion of hematopoietic progenitors and decreases the number of BM lymphocytes in the BM hematopoietic niche accompanied with a decreased expression of SDF-1 and a decrease in Flk2-expressing KSL cells (120) .
Although two-dimensional (2D) cellular in vitro niche-like microenvironments have been useful for the expansion of immature HSPCs, three-dimensional (3D) architecture proved to be more effective. 3D-modified microwell cultures with HSCs and cytokines called micromarrows resulted in twice the expansion of HSCs as compared with 2D controls (121) . Use of bioreactors epitomizes the 3D structure of the BM. Along with the physical immobilization of ligands for HSC expansion, use of bioreactors allow for the effective utilization of the media and provide an optimized cost-effective strategy (122) . Large scale bioreactors, such as DIDECO Pluricell system, are used for the routine manufacture of mature blood cells to enable hematopoietic support for chemotherapy patients (123) . Biomaterials play a crucial role to provide a 3D template of synthetic extracellular-matrix environment called scaffolds. Stem cells show effective ex vivo HSC proliferative response to a variety of natural or synthetic scaffolds when these scaffolds are supplied in their optimum growth milieu or in a microenvironment (124) . An understanding of how to create local microenvironments (niches) serves as a platform to receive and guide the integration of transplanted stem cells.
Leukemic stem cells niche
De-regulated niche signaling interactions and pathways hinder normal hematopoiesis directly or indirectly under pathological circumstances such as hematologic malignancies or myelodysplasia (125) . Lane et al. (126) reported that leukemia stem cells (LSCs) are eliminated from the therapeutic strategy as they remain hidden by replicating the same quiescence mechanisms as normal stem cells within the BM niche during chemotherapy. Eventually, these LSCs perpetuate disease relapse. As competitive interactions between healthy HSCs and LSCs depend on cell dose, the elimination of LSC niche interactions would improve replacement with healthy HSPCs (127) .
Leukemic myeloid cells stimulate MSCs to generate transformed osteoblasts, which accumulate as myelofibrotic cells. TGF-β, notch, and inflammatory cytokine signaling changes remodel the endosteal BM niche into a self-reinforcing leukemic niche to favor LSC function (128) . Additionally, deregulated Wnt signaling is implicated in the development of hematological malignancies. Therefore, focusing on anomalous Wnt signaling may be a direct avenue to affect LSCs; this is in contrast with the conventional chemotherapy that is generally not convincingly adequate for targeting leukemiainitiating cells (81) . β-catenin was shown to be significant in the survival of leukemic cells in chronic myeloid leukemia (70) . Advanced stage of leukemic samples from both murine and human models also demonstrated that pre-leukemic stem cells and HSCs are sustained by niche-derived Wnt signals. Secreted frizzled-related protein genes (sFRPs) become inactivated by the hypermethylation of their promoter in acute lymphoid and myeloid leukemia. Methylation of Wnt antagonists shows diagnostic significance in acute myeloid leukemia (64) . Hoffmeyer et al. (129) reported the selective binding of β-catenin to human telomerase reverse transcriptase (hTERT) promoter in human carcinoma cells. TCF4, out of the four members of the LEF/TCF family, displayed more efficient activation on the hTERT promoter, which is the decisive factor for the β-catenin/TCF4-dependent expression (130) . Recently, it has been investigated that transcription factors TCF1 and LEF1 interact and synergize with members of the activating transcription factor 2 (ATF2) family of transcription factors to bolster the advancement of hematopoietic malignancies in the absence of β-catenin (131) . Notch signaling and its genes mutations possibly possess the ability to regulate the development of malignant cell types (132) . Recently, a correlation has been established between Notch target genes and histone H3K4 me3. When histone H3K4 me3 fails to recognize its target sites, this alters Notch1-targeted genes concurrently and induces oncogenicity. Likewise, the mutations of histone PHF6 are unified with mutations in Notch1 in T-cell acute lymphoblastic leukemia (T-ALL) (133) . PHF6 is a direct target for anti-cancer therapy in tumors that depend on cooperating mutations for their progression such as T-ALL (134, 135) . Typically, Notch signaling accelerates the binding of RBPJ (Notch/ RBPJ) to the miR-155 promoter (Notch/ RBPJ/miR-155), thereby inhibiting microRNA (miR-155) expression. Loss of Notch/RBPJ signaling amplifies miR-155 in BM endothelial cells that enables miR-155-mediated targeting of the nuclear factor κB (NF-κB) inhibitor κB-Ras1 and NF-κB activation (Notch/miR-155/κB-Ras1/ NF-κB). This signaling axis stimulates the secretion of pro-inflammatory disorders (136) . Disruption of niche regulation by stromal defects in gene expression can lead to the prominence of leukemic malignancy. BM stroma apparently exerts distinctive selection criteria that buttress leukemic cells and imparts a disadvantage to normal hematopoietic cells (137) . Presumably, leukemia cells attain the capacity to react disparately to physiological niche signals as opposed to regular HSCs. For example, TGF-β imposes the dormancy of normal HSCs (138), while it increases the survival and proliferation of leukemiainitiating cells in a model of chronic myelogenous leukemia (139) . CXCR4 and SDF-1 also play roles in tumor growth and metastasis. CXCR7 is considered as another receptor for SDF-1. The appearance of CXCR7 in the metastasis of tumor cells is also emanated (140) . Antagonists (plerixaflor, AMD3100) that disrupt CXCR4/SDF-1 interaction are increasingly employed clinically to mobilize HSPCs from the BM (141) . Notch inhibitors are extremely attractive candidates for therapeutic genetic intervention at molecular stem cell level. As Wnt and Shh signaling pathways are also essential for the expansion of leukemia cells, addition of their inhibitors improve the efficacy of Notch inhibitors (142, 143) . Methodologies based on miRNAs as dominant activators or suppressors of gene activity in LSCs have emerged as encouraging techniques for eliminating LSCs (144) . The clinical exploitation of HIF-1α for therapeutic implications is contradictory because of inconsistent results obtained so far (145) . HSC niche modulator, estrogen signaling, has been reported to arrest myeloproliferative neoplasm in vivo (146) . Erythropoietin and deranged iron metabolism fine-tune blood regeneration as these endocrine factors are conducive to hematopoietic cell maintenance, self-renewal, and differentiation (147) .
Conclusions
The identification and characterization of hematopoietic niche during the past decade of research presents a discernible cognizance on BM niche regulation. To investigate species-specific microenvironmental influences, a unique human-mouse hybrid model was designed that allows the engraftment and growth of the number of normal and malignant hematopoietic progenitors. Bioluminescent imaging was used to follow engraftment by implanting human bone particles in immunodeficient RAG2 −/−γc−/− mice. The generation of human bone from MSCs in biphasic calcium phosphate scaffolds formulates an environment capable of corroborating hematopoiesis (148) . Recently, biomimetic microdevice "bone marrow-on-a-chip" has been devised allowing the culture of live BM with an operative hematopoietic niche in vitro. This was done by first engineering new bone in vivo, expelling it outright and perfusing it with culture medium in a microfluidic device. Such engineered BM models recapitulate niche interactions as in in vivo for a week, thereby offering a new approach for the study of hematopoiesis and hematological diseases in vitro (149) . Advanced technological overtures and progressively sophisticated experimental models will allow us to decipher unfamiliar aspects of the HSC niche.
The full ramifications of coordination between the osteoblastic niche and the vascular niche activity have been under-appreciated and merits future investigation. Whether these niches provide concomitant or redundant regulation of HSC fate or provide wholly unique regulatory functions is still an unresolved question. Further interrogative point is how many functionally distinct HSC niches exist and whether they are spatially discriminative. Moreover, the mechanisms through which the vascular niche regulates HSC fate still remain enigmatic (150) . Furthermore, HSC-niche interactions of stem cell and leukemic HSCs may serve as a paradigm for designing strategies for therapeutic ex vivo expansion and for understanding the bifold nature of self-renewal signals. More appropriate understanding of the cellular and molecular basis of the niche will allow us to resolve the regulation of stem cell self-renewal. Besides, LSCs show resistance to most types of therapy because of the propensity of stem cell quiescence, expression of high levels of ATP-binding cassette pumps, and their localization in different niches (126) . These hurdles could be resolved through insights gained from the knowledge of niche signaling mechanistic underpinnings.
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